Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Salvatore Giovanni, Laganà, Antonio Simone, Capriglione, Stella, Angioli, Roberto, La Rosa, Valentina Lucia, Lopez, Salvatore, Valenti, Gaetano, Sapia, Fabrizio, Sarpietro, Giuseppe, Butticè, Salvatore, Tuscano, Carmelo, Fanale, Daniele, Tropea, Alessandro, Rossetti, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455008/
https://www.ncbi.nlm.nih.gov/pubmed/28531111
http://dx.doi.org/10.3390/ijms18051100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455008/
https://www.ncbi.nlm.nih.gov/pubmed/28531111
http://dx.doi.org/10.3390/ijms18051100

Ejemplares similares